<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Nucleic Acid Ther</journal-id><journal-id journal-id-type="iso-abbrev">Nucleic Acid Ther</journal-id><journal-id journal-id-type="pmc-domain-id">1588</journal-id><journal-id journal-id-type="pmc-domain">nat</journal-id><journal-id journal-id-type="publisher-id">nat</journal-id><journal-title-group><journal-title xml:lang="en">Nucleic Acid Therapeutics</journal-title></journal-title-group><issn pub-type="ppub">2159-3337</issn><issn pub-type="epub">2159-3345</issn><publisher><publisher-name>Mary Ann Liebert, Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC3426203</article-id><article-id pub-id-type="pmcid-ver">PMC3426203.1</article-id><article-id pub-id-type="pmcaid">3426203</article-id><article-id pub-id-type="pmcaiid">3426203</article-id><article-id pub-id-type="pmid">22913596</article-id><article-id pub-id-type="doi">10.1089/nat.2012.0371</article-id><article-id pub-id-type="publisher-id">10.1089/nat.2012.0371</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Toxicological and Pharmacokinetic Properties of Chemically Modified siRNAs Targeting p53 RNA Following Intravenous Administration</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Thompson</surname><given-names initials="JD">James D.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kornbrust</surname><given-names initials="DJ">Douglas J.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Foy</surname><given-names initials="JWD">Jeffrey W-D.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Solano</surname><given-names initials="ECR">Elisabeth C.R.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schneider</surname><given-names initials="DJ">David J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Feinstein</surname><given-names initials="E">Elena</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Molitoris</surname><given-names initials="BA">Bruce A.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Erlich</surname><given-names initials="S">Shai</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><aff id="aff1"><label><sup>1</sup></label><institution>Quark Pharmaceuticals, Inc.</institution>, Boulder, Colorado.</aff><aff id="aff2"><label><sup>2</sup></label><institution>Preclinsight</institution>, Reno, Nevada.</aff><aff id="aff3"><label><sup>3</sup></label><institution>QBI Enterprises, Ltd</institution>. Ness Ziona, <country>Israel</country>.</aff><aff id="aff4"><label><sup>4</sup></label>Department of Medicine, Division of Nephrology and Indiana Center for Biological Microscopy, <institution>Indiana University School of Medicine</institution>, Indianapolis, Indiana.</aff><aff id="aff5"><label><sup>5</sup></label><institution>Quark Pharmaceuticals, Inc.</institution>, Fremont, California.</aff></contrib-group><author-notes><corresp>Address correspondence to: <italic>James D. Thompson, Ph.D., Quark Pharmaceuticals, Inc., 2990 Wilderness Place, Boulder, CO 80301. E-mail:</italic><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:jthompson@quarkpharma.com">jthompson@quarkpharma.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2012</year></pub-date><volume>22</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">213317</issue-id><fpage>255</fpage><lpage>264</lpage><history><date date-type="received"><day>05</day><month>6</month><year>2012</year></date><date date-type="accepted"><day>12</day><month>7</month><year>2012</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>08</month><year>2012</year></date></event><event event-type="pmc-live"><date><day>29</day><month>08</month><year>2012</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2012-08-30 00:20:23.513"><day>30</day><month>08</month><year>2012</year></date></event></pub-history><permissions><copyright-statement>Copyright 2012, Mary Ann Liebert, Inc.</copyright-statement><copyright-year>2012</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nat.2012.0371.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nat.2012.0371.pdf"/><abstract><p>We report the toxicological and pharmacokinetic properties of the synthetic, small interfering RNA I5NP following intravenous administration in rodents and nonhuman primates. I5NP is designed to act via the RNA interference (RNAi) pathway to temporarily inhibit expression of the pro-apoptotic protein p53 and is being developed to protect cells from acute ischemia/reperfusion injuries such as acute kidney injury that can occur during major cardiac surgery and delayed graft function that can occur following renal transplantation. Following intravenous administration, I5NP was very rapidly cleared from plasma was distributed predominantly to the kidney, with very low levels in liver and other tissues. Doses of 800&#8201;mg/kg I5NP in rodents, and 1,000&#8201;mg/kg I5NP in nonhuman primates, were required to elicit adverse effects, which in the monkey were isolated to direct effects on the blood that included a sub-clinical activation of complement and slightly increased clotting times. In the rat, no additional adverse effects were observed with a rat analogue of I5NP, indicating that the effects likely represent class effects of synthetic RNA duplexes rather than toxicity related to the intended pharmacologic activity of I5NP. Taken together, these data support clinical testing of intravenous administration of I5NP for the preservation of renal function following acute ischemia/reperfusion injury.</p></abstract><counts><fig-count count="5"/><table-count count="3"/><ref-count count="18"/><page-count count="10"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>